NOVOXEL

Novoxel® was founded in 2011 with the vision to revolutionize fractional skin rejuvenation by creating new and better types of treatments for physicians and patients. We work in close collaboration with the medical community to achieve this goal and have leading physicians on our advisory panel. Our TMA® technology is a game-changer: a patient-friendly technology for fractional skin resurfacing that is green, versatile - and shown to be safe in clinical studies. Today, our patented products and technology are marketed in over 30 countries worldwide. We will continue to redefine the aesthetics landscape by pushing the boundaries through developing novel solutions and ensuring excellence in everything we do.

Also known as: Novoxel GmbH, Novoxel® LTD.

Primary location: Berlin Germany